Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology.
Diretrizes para o tratamento farmacológico da COVID-19. Consenso da Associação de Medicina Intensiva Brasileira, da Sociedade Brasileira de Infectologia e da Sociedade Brasileira de Pneumologia e Tisiologia.
Journal
Revista Brasileira de terapia intensiva
ISSN: 1982-4335
Titre abrégé: Rev Bras Ter Intensiva
Pays: Brazil
ID NLM: 9506692
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
15
05
2020
accepted:
18
05
2020
entrez:
16
7
2020
pubmed:
16
7
2020
medline:
30
7
2020
Statut:
ppublish
Résumé
Different therapies are currently used, considered, or proposed for the treatment of COVID-19; for many of those therapies, no appropriate assessment of effectiveness and safety was performed. This document aims to provide scientifically available evidence-based information in a transparent interpretation, to subsidize decisions related to the pharmacological therapy of COVID-19 in Brazil. A group of 27 experts and methodologists integrated a task-force formed by professionals from the Brazilian Association of Intensive Care Medicine (Associação de Medicina Intensiva Brasileira - AMIB), the Brazilian Society of Infectious Diseases (Sociedad Brasileira de Infectologia - SBI) and the Brazilian Society of Pulmonology and Tisiology (Sociedade Brasileira de Pneumologia e Tisiologia - SBPT). Rapid systematic reviews, updated on April 28, 2020, were conducted. The assessment of the quality of evidence and the development of recommendations followed the GRADE system. The recommendations were written on May 5, 8, and 13, 2020. Eleven recommendations were issued based on low or very-low level evidence. We do not recommend the routine use of hydroxychloroquine, chloroquine, azithromycin, lopinavir/ritonavir, corticosteroids, or tocilizumab for the treatment of COVID-19. Prophylactic heparin should be used in hospitalized patients, however, no anticoagulation should be provided for patients without a specific clinical indication. Antibiotics and oseltamivir should only be considered for patients with suspected bacterial or influenza coinfection, respectively. So far no pharmacological intervention was proven effective and safe to warrant its use in the routine treatment of COVID-19 patients; therefore such patients should ideally be treated in the context of clinical trials. The recommendations herein provided will be revised continuously aiming to capture newly generated evidence.
Identifiants
pubmed: 32667444
pii: S0103-507X2020000200166
doi: 10.5935/0103-507x.20200039
pmc: PMC7405746
pii:
doi:
Types de publication
Consensus Development Conference
Journal Article
Practice Guideline
Langues
eng
por
Sous-ensembles de citation
IM
Pagination
166-196Références
Blood Adv. 2019 Dec 10;3(23):3898-3944
pubmed: 31794602
Crit Care. 2020 May 19;24(1):241
pubmed: 32430057
J Med Virol. 2020 Jul;92(7):814-818
pubmed: 32253759
JAMA. 2020 May 19;323(19):1897-1898
pubmed: 32208486
Lancet Respir Med. 2020 Mar;8(3):267-276
pubmed: 32043986
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Clin Infect Dis. 2020 Jun 16;:
pubmed: 32556191
MMWR Morb Mortal Wkly Rep. 2020 Feb 21;69(7):177-182
pubmed: 32078591
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
BMJ. 2020 May 14;369:m1849
pubmed: 32409561
Vaccines (Basel). 2018 May 21;6(2):
pubmed: 29883414
Health Res Policy Syst. 2018 Jul 13;16(1):63
pubmed: 30005679
Lancet. 2020 May 30;395(10238):1695-1704
pubmed: 32401715
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219
pubmed: 32391667
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Infect. 2020 Jul;81(1):e21-e23
pubmed: 32283143
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
JAMA Cardiol. 2020 Sep 01;5(9):1036-1041
pubmed: 32936252
J Am Coll Cardiol. 2020 Jun 16;75(23):2992-2993
pubmed: 32330546
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
J Am Heart Assoc. 2020 Jun 16;9(12):e017144
pubmed: 32463348
Travel Med Infect Dis. 2020 Mar - Apr;34:101663
pubmed: 32289548
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
N Engl J Med. 2020 Jul 16;383(3):e12
pubmed: 32343505
Chest. 2020 Sep;158(3):864-865
pubmed: 32387517
J Am Soc Nephrol. 2020 Jun;31(6):1150-1156
pubmed: 32317402
Lancet Infect Dis. 2020 Oct;20(10):1135-1140
pubmed: 32526193
BMJ. 2017 Sep 21;358:j4008
pubmed: 28935701
J Clin Epidemiol. 2017 Nov;91:47-53
pubmed: 28911999
Med. 2020 Dec 18;1(1):114-127.e3
pubmed: 32838355
JAMA Netw Open. 2020 Apr 24;3(4):e208857
pubmed: 32330277
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Travel Med Infect Dis. 2020 May - Jun;35:101738
pubmed: 32387409
Syst Rev. 2015 Jan 14;4:4
pubmed: 25589399
Med Mal Infect. 2020 Jun;50(4):384
pubmed: 32240719
Pharmacol Res. 2020 Jul;157:104874
pubmed: 32360581
Lancet. 2015 May 2;385(9979):1729-1737
pubmed: 25640810
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Clin Infect Dis. 2019 Mar 5;68(6):e1-e47
pubmed: 30566567
Signal Transduct Target Ther. 2020 Feb 21;5(1):18
pubmed: 32296012
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
J Med Virol. 2020 Oct;92(10):1922-1931
pubmed: 32297985
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Clin Transl Sci. 2020 Nov;13(6):1087-1095
pubmed: 32881340
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Leukemia. 2020 Jun;34(6):1503-1511
pubmed: 32372026